{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:24:41Z","timestamp":1782800681032,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","award":["5U01HL080416"],"award-info":[{"award-number":["5U01HL080416"]}],"id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006686","name":"University of Miami","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020834","name":"Miami Heart Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.amjcard.2023.04.022","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T15:30:23Z","timestamp":1683905423000},"page":"124-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impact of Diabetes Mellitus on Benefit of \u03b2-Blocker Therapy After Myocardial Infarction"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7702-1913","authenticated-orcid":false,"given":"Ghaith","family":"Zaatari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Blandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dawn","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Suba\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-1851","authenticated-orcid":false,"given":"Jeffrey J.","family":"Goldberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.04.022_bib0001","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2337\/diacare.28.12.2901","article-title":"Type 2 diabetes as a \u201ccoronary heart disease equivalent\u201d: an 18-year prospective population-based study in Finnish subjects","volume":"28","author":"Juutilainen","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0002","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2337\/dc09-0680","article-title":"Mortality trends in subjects with and without diabetes during 33 years of follow-up","volume":"33","author":"Jansson","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0003","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jama.280.7.623","article-title":"National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: national cooperative cardiovascular project [published correction appears in JAMA 1999;281:37]","volume":"280","author":"Krumholz","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0004","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199808203390801","article-title":"Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction","volume":"339","author":"Gottlieb","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0005","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2013.04.102","article-title":"Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction","volume":"62","author":"Arnold","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0006","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","article-title":"Effect of beta-blocker dose on survival after acute myocardial infarction","volume":"66","author":"Goldberger","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0007","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oxfordjournals.eurheartj.a061845","article-title":"A randomised placebo-controlled international trial. The MIAMI Trial Research Group","volume":"6","year":"1985","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0009","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","article-title":"Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomised trial","volume":"2","author":"Hjalmarson","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0010","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0011","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0013","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0735-1097(94)00552-2","article-title":"Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice","volume":"25","author":"Viskin","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0014","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/dom.12827","article-title":"Long-term mortality after acute myocardial infarction among individuals with and without diabetes: a systematic review and meta-analysis of studies in the post-reperfusion era","volume":"19","author":"Gholap","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0015","first-page":"372","article-title":"Association between \u03b2-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry","volume":"10","author":"Mars","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0016","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1253\/circj.CJ-18-0662","article-title":"Prognostic impact of \u03b2-blocker dose after acute myocardial infarction","volume":"83","author":"Hwang","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019017","article-title":"One-year landmark analysis of the effect of beta-blocker dose on survival after acute myocardial infarction","volume":"10","author":"Goldberger","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.repc.2017.06.022","article-title":"Effect of beta-blocker dose on mortality after acute coronary syndrome","volume":"37","author":"Raposeiras-Roubin","year":"2018","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.amjcard.2020.09.044","article-title":"Optimal dose and type of \u03b2-blockers in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"137","author":"Park","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.amjcard.2018.05.038","article-title":"Effect on mortality of higher versus lower \u03b2-blocker (metoprolol succinate or carvedilol) dose in patients with heart failure","volume":"122","author":"Ajam","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2014.04.018","article-title":"Type of \u03b2-blocker use among patients with versus without diabetes after myocardial infarction","volume":"168","author":"Arnold","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0022","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1463-1326.2008.00927.x","article-title":"Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients","volume":"11","author":"Bell","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0023","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.21.4.631","article-title":"Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension","volume":"21","author":"Giugliano","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021310","article-title":"Long-term mortality associated with use of carvedilol versus metoprolol in heart failure patients with and without type 2 diabetes: a Danish Nationwide Cohort Study","volume":"10","author":"Schwartz","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1464-5491.2004.01116.x","article-title":"Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications","volume":"21","author":"Song","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjcard.2023.04.022_bib0026","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2337\/diacare.25.8.1410","article-title":"Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK prospective diabetes Study 61","volume":"25","author":"Colagiuri","year":"2002","journal-title":"Diabetes Care"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923002321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923002321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:07:36Z","timestamp":1762078056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923002321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"alternative-id":["S0002914923002321"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.04.022","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Diabetes Mellitus on Benefit of \u03b2-Blocker Therapy After Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}